Joel J Earlywine1, Angela R Bazzi2, Katie B Biello3, R Monina Klevens4. 1. From the Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, Massachusetts; Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts. 2. Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts. Electronic address: abazzi@bu.edu. 3. Center for Health Promotion and Health Equity, Brown University, Providence, Rhode Island; Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island; Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island; The Fenway Institute, Fenway Health, Boston, Massachusetts. 4. Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts.
Abstract
INTRODUCTION: In Massachusetts, recent outbreaks of HIV have been fueled by injection and sexual exposures among people who inject drugs. Understanding pre-exposure prophylaxis need, knowledge, and use among people who inject drugs will help inform and evaluate interventions. METHODS: In 2019, investigators analyzed 2018 National HIV Behavioral Surveillance data from people who inject drugs in Boston, MA, who met eligibility criteria. Proportions of people who inject drugs with U.S. Preventive Services Task Force-based pre-exposure prophylaxis indication were estimated by types of HIV acquisition risk in the past year: injection exposure only, sexual exposure only, and overlapping injection and sexual exposures. Investigators then evaluated pre-exposure prophylaxis awareness, conversations with healthcare providers about pre-exposure prophylaxis, and self-reported pre-exposure prophylaxis use among those with and without pre-exposure prophylaxis indications. RESULTS: The prevalence of pre-exposure prophylaxis indication was 92% overall (389/423), with 290 (69%) participants indicated for injection exposures only, 3 (<1%) indicated for sexual exposures only, and 96 (23%) indicated for both injection and sexual exposures. Among those indicated for pre-exposure prophylaxis (n=389), 152 (39%) reported being aware of pre-exposure prophylaxis, 41 (11%) had discussed pre-exposure prophylaxis with a healthcare provider, and 8 (2%) had used pre-exposure prophylaxis in the past year. There were no statistically significant differences between pre-exposure prophylaxis‒indicated and ‒nonindicated people who inject drugs with respect to pre-exposure prophylaxis awareness, discussion with a healthcare provider, and pre-exposure prophylaxis use. CONCLUSIONS: Indication for pre-exposure prophylaxis was high, but awareness was low, conversations about pre-exposure prophylaxis with healthcare providers were uncommon, and pre-exposure prophylaxis use was extremely low. These findings highlight important areas for clinical and community-based interventions to improve pre-exposure prophylaxis uptake among and delivery to people who inject drugs.
INTRODUCTION: In Massachusetts, recent outbreaks of HIV have been fueled by injection and sexual exposures among people who inject drugs. Understanding pre-exposure prophylaxis need, knowledge, and use among people who inject drugs will help inform and evaluate interventions. METHODS: In 2019, investigators analyzed 2018 National HIV Behavioral Surveillance data from people who inject drugs in Boston, MA, who met eligibility criteria. Proportions of people who inject drugs with U.S. Preventive Services Task Force-based pre-exposure prophylaxis indication were estimated by types of HIV acquisition risk in the past year: injection exposure only, sexual exposure only, and overlapping injection and sexual exposures. Investigators then evaluated pre-exposure prophylaxis awareness, conversations with healthcare providers about pre-exposure prophylaxis, and self-reported pre-exposure prophylaxis use among those with and without pre-exposure prophylaxis indications. RESULTS: The prevalence of pre-exposure prophylaxis indication was 92% overall (389/423), with 290 (69%) participants indicated for injection exposures only, 3 (<1%) indicated for sexual exposures only, and 96 (23%) indicated for both injection and sexual exposures. Among those indicated for pre-exposure prophylaxis (n=389), 152 (39%) reported being aware of pre-exposure prophylaxis, 41 (11%) had discussed pre-exposure prophylaxis with a healthcare provider, and 8 (2%) had used pre-exposure prophylaxis in the past year. There were no statistically significant differences between pre-exposure prophylaxis‒indicated and ‒nonindicated people who inject drugs with respect to pre-exposure prophylaxis awareness, discussion with a healthcare provider, and pre-exposure prophylaxis use. CONCLUSIONS: Indication for pre-exposure prophylaxis was high, but awareness was low, conversations about pre-exposure prophylaxis with healthcare providers were uncommon, and pre-exposure prophylaxis use was extremely low. These findings highlight important areas for clinical and community-based interventions to improve pre-exposure prophylaxis uptake among and delivery to people who inject drugs.
Authors: Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi Journal: Drug Alcohol Depend Date: 2019-03-08 Impact factor: 4.492
Authors: E Jennifer Edelman; Brent A Moore; Sarah K Calabrese; Gail Berkenblit; Chinazo Cunningham; Viraj Patel; Karran Phillips; Jeanette M Tetrault; Minesh Shah; David A Fiellin; Oni Blackstock Journal: AIDS Behav Date: 2017-04
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Susan J Curry; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2019-06-11 Impact factor: 56.272
Authors: Angela R Bazzi; Chad J Valasek; Samantha A Streuli; Carlos F Vera; Alicia Harvey-Vera; Morgan M Philbin; Katie B Biello; Alexis M Roth; Steffanie A Strathdee; Heather A Pines Journal: AIDS Patient Care STDS Date: 2022-06-21 Impact factor: 5.944
Authors: Eugene S G Massey; Angela R Bazzi; Carlos R Sian; Christina M Gebel; Judith A Bernstein; Sabrina A Assoumou Journal: AIDS Care Date: 2022-02-02
Authors: Suzan M Walters; David Frank; Brent Van Ham; Jessica Jaiswal; Brandon Muncan; Valerie Earnshaw; John Schneider; Samuel R Friedman; Danielle C Ompad Journal: AIDS Behav Date: 2021-10-09
Authors: Benedikt Pleuhs; Colleen B Mistler; Katherine G Quinn; Julia Dickson-Gomez; Jennifer L Walsh; Andrew E Petroll; Steven A John Journal: J Prim Care Community Health Date: 2022 Jan-Dec